Adenovirus hexon modification for enhanced vaccine vectors
A vaccine platform technology that introduces large antigen or peptide insertions into ChAdOx2 adenoviral hexon regions, including a newly identified HVR7 site. The approach enables surface display of epitopes and protein-coupling tags, enhancing antibody responses while maintaining transgene delivery and T-cell immunogenicity.
Applications: Vaccines, gene therapy, cancer immunotherapy
| Features | Benefits |
|---|---|
| Enables surface presentation of epitopes | Expands antigen design flexibility for vaccine developers |
| Novel HVR7 hexon insertion site for antigen display | Supports large peptide insertions in multiple hexon regions |
| Expands antigen design flexibility for vaccine developers | Reduces reliance on separate nanoparticle or VLP platforms |
| Maintains adenoviral vector infectivity and transgene delivery | Applicable to infectious disease, cancer, and gene therapy strategies |
Patented and Available For
- Co-development
- Consulting
- Licensing